Professor Alexander E Berezin
Paracelsus Private Medical University, Salzburg (Austria)
Membership:
FESC Member
Biography
Dr. Alexander E. Berezin has received PhD in 1994 in the State Medical University of Zaporozhye (Ukraine). He is currently working as Senior Consultant, Lecturer and Professor of Medicine in the State Medical University of Zaporozhye (Ukraine). His research goals are fundamental study of biological markers, the development of cardiovascular prevention and rehabilitation. Based on this research and training in heart failure he has received several awards and honors. He has a regional and national profile. He has published 1050 papers and more in reputed journals, 57 books/chapters and has been serving as an editorial board member of repute.
Contributor content
Presentation
Predictors of kidney-related outcomes in chronic heart failure patients with concomitant type 2 diabetes mellitus treated with dapagliflozin
Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
Presentation
Circulating levels of erythrocytes-derived vesicles related to poor glycaemia control in heart failure patients with type 2 diabetes mellitus
Presentation
Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure
Presentation
Circulating Levels of erythrocytes-derived vesicles are associated with glucose control in type 2 diabetes mellitus patients with atrial fibrillation
Presentation
Low serum irisin levels predicted newly atrial fibrillation in patients with any phenotypes of chronic heart failure
Presentation
Circulating levels of erythrocytes-derived vesicles related to poor glycaemia control in type 2 diabetes mellitus patients with atrial fibrillation
Presentation
Low irisin levels predict acutely decompensated heart failure in type 2 diabetes mellitus patients
Presentation
The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus
Presentation
